Member Info for desamax

Because of the recent Toc study event, Sareum is highly likely to issue an immediate RNS announcement upon completing its 16-week toxicity study.

It's possibile that the Contract Research Organization will need extra time to process samples, conduct histopathology, and write the audited, final GLP study report. So this could ponentialy take us to up to 20 weeks before any announcements.

Fingers crossed Receptor.AI's AI platform for virtual screening and molecular design with Sareum’s expertise in kinase inhibitors are progressing nicely

Isomorphic Labs is utilizing its AI-driven drug design engine, which builds on AlphaFold 3, to advance a pipeline that includes targets in the TYK2/JAK1 signaling pathway. The company, founded by Demis Hassabis and spun out of Google DeepMind, focuses on designing small molecules to modulate these proteins for immune-mediated diseases.Key Aspects of Isomorphic Labs' Approach to TYK2/JAK1:AI-Driven Discovery: Isomorphic Labs uses "digital biology" to predict the structure of protein-ligand complexes, exceeding the capabilities of AlphaFold 3 to identify new binding pockets on target proteins.Targeting JAK/STAT Pathway: The company's models are applied to challenging targets, such as TYK2, specifically focusing on allosteric inhibition (binding to the regulatory JH2 domain rather than the ATP active site) to improve selectivity and reduce side effects.Partnerships: As of early 2026, Isomorphic Labs has entered into major research collaborations with pharmaceutical companies like Johnson & Johnson to accelerate drug discovery across various targets, potentially including JAK/TYK2 pathways.Context in Industry: Dual inhibition of TYK2 and JAK1 is known to be more effective than single inhibition for diseases like psoriasis. While other companies have developed inhibitors like deucravacitinib (TYK2) and brepocitinib (TYK2/JAK1), Isomorphic Labs aims to create superior molecules using AI.Note: While Isomorphic Labs develops its own pipeline, specific, publicly named small-molecule candidates from them for TYK2/JAK1 are often part of confidential partner programs, though their AI capabilities are actively aimed at this area.

Not Sar related but a deal for Ai tyk2 jak Phama, bigger profile too. But who knows, I wonder what our experts think of this deal? ....

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital with significant participation from Alphabet and GV. They are joined at the table by new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. We're thrilled to have their combined expertise on board.

This milestone funding accelerates our ability to develop the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: accelerating and expanding our pipeline of therapeutic programs driving toward the clinic. By transforming drug discovery with proprietary AI at the core, we are positioned to deliver scientific breakthroughs with a level of precision that was previously unthinkable.

To power this next phase of growth, the funding will also support scaling our expertise; integrating world-class AI, engineering, drug design, and clinical expertise across our global sites. This scale is crucial to our long-term vision of applying AI-driven breakthroughs to the most complex biological challenges and addressing the global burden of disease. Our goal is to bring life-changing medicines to patients who need them most.

We are grateful to our incredible team, partners, and investors who share our ultimate mission: to one day solve all disease with the help of AI.

Read the full announcement here: bit.ly/4v2OI03

For what it worth ....

participants in a toxicology or clinical study are typically monitored for a period after the study is halted early, even if the termination was not due to faults with the compound.

Safety monitoring remains a primary concern for the sponsor and research team to ensure no delayed adverse effects occur, regardless of the reason for closure.Key Points Regarding Post-Study MonitoringSafety Reporting Obligation: If a study is terminated early, the sponsor must report this to regulatory authorities (e.g., MHRA, FDA) and include a detailed plan for the follow-up of participants.Follow-up Procedures: Even if the compound is safe, the protocol likely requires "recovery" or "washout" periods to ensure the compound clears the system, especially for compounds with long half-lives (e.g., up to 5-7 half-lives).Participant Care: The research team has an ethical responsibility to ensure the safe transition of participants out of the study. This might include final safety assessments (e.g., blood work, physical exams) to verify safety.Duration of Monitoring: The length of monitoring depends on the pharmacokinetic data of the compound and is specified in the study’s early termination procedures.

Even though the previous Tox study was halted the animals would still have to have been monitored for a good while after.

Nothing has been brought to light regarding this. This must add to the positivity of all going to plan. GLA

Someone want to load up we could see TR1 this week, the name will set the cat amongst the pigeons.

Not many sells with this spread, if MMs want stock they need to offer a better price, sticky hands atm waiting for the over due news that's we all know is coming.

Got to love the 10% or so drop to suck up the stop losses. Happens every time.

Millions and millions bought today not seen vol like that since the 3p days, the sp must be on its way back and possibly way past 3p next week. We all know the news is imminent. And it's going to be blockbusting.

MMS want your shares, who is willing to cash in and be out come Mon am ? Certainly not me !!!

Penny on the horizon then multi bags from there, we all know news is comming and it's going to be very good news at that. Don't be like the man who fell out of the ballon !!!

29.5 on the offer could we be in the 30s to sell by end of day ?

@potnak 👍

Can someone remind me, was it a bod decision to do the Tox study or did a potential partner advise them to do it ?

.40 to buy .29.6 to selll lol

Weather it's tomorrow or not, we all know it's coming. They will be plenty in the queue first thing as this is only going one way from here 🚀🚀🚀

@ porky

a broken clock is right twice a day.

Regarding the CRO and the possibility of making a claim, this happened with another company I was involved with. If the claim is a strong as Parker suggested as a professional company they should have at least been advised of the option below.

A strict timetable had been set for the next stage of the claim (18 January 2020) and without suitable submission, again xx was at risk in the proceedings.

It was agreed that we would explore the possibility of finding a third party to acquire the litigation, and several offers were received. Following consideration of the offers, terms were agreed on a 70:30 split in favour of fix(70% of the net litigation proceeds will be received by xx The offer also contained an express indemnity for the benefit of xx,which was very important.

Given the size of the claim and the overall circumstances, it was agreed with the committee members that this was in the best interests of creditors and investors, and we proceeded to conclude the sale of the litigation on 15 January 2020.

The third party will provide regular updates, which will be shared where possible.